SCHEMBL1126497

SCHEMBL1126497

CCOC(=O)CC(=O)c1ccco1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.56
FEN1 P39748 1/20 0.56
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
HTT P42858 1/20 0.50
ALDH1A1 P00352 8/20 0.49
POLB P06746 4/20 0.49
HSD17B10 Q99714 3/20 0.49
ALOX15 P16050 2/20 0.49
LMNA P02545 1/20 0.49
KMT2A Q03164 2/20 0.48
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
MAPT P10636 4/20 0.47
TDP1 Q9NUW8 4/20 0.47
HPGD P15428 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
RECQL P46063 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29054123 0.98 ERCC5 (0.54) ERCC5FEN1NPC1RAB9ASMN1; SMN2
SCHEMBL6157657 0.85 ALDH1A1 (0.51) ERCC5FEN1NPC1RAB9ASMN1; SMN2
SCHEMBL28020549 0.85 ERCC5 (0.57) ERCC5FEN1SMN1; SMN2HTTALDH1A1
SCHEMBL4459612 0.84 ERCC5 (0.61) ERCC5FEN1NPC1RAB9ASMN1; SMN2
SCHEMBL591778 0.84 ERCC5 (0.61) ERCC5FEN1NPC1RAB9ASMN1; SMN2
SCHEMBL3379620 0.81 ALDH1A1 (0.48) ERCC5FEN1NPC1RAB9ASMN1; SMN2
SCHEMBL6320074 0.80 ERCC5 (0.74) ERCC5FEN1NPC1RAB9ASMN1; SMN2
SCHEMBL12882119 0.80 ALDH1A1 (0.65) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL859237 0.79 NPC1 (0.61) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL5161664 0.79 ERCC5 (0.54) ERCC5FEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1405917-B1 Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction SALTIGO GMBH (DE) 2013-08-14 EP claimed
US-20040181058-A1 Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2004-09-16 US claimed
CN-1497048-A Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative 拜尔公司 2004-05-19 CN claimed
EP-1405917-A2 Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction Bayer Chemicals AG (DE) 2004-04-07 EP claimed
CN-119775241-A 5-Hydroxy benzofuran derivative and preparation method thereof 华东理工大学 2025-04-08 CN disclosed
CN-119330931-A Synthesis method of 2- (benzenesulfonamide) -3-oxo-3-heterocyclic propionate compound 郑州大学 2025-01-21 CN disclosed
CN-116554029-B Synthesis method of aromatic formyl ethyl acetate 河北民族师范学院 2024-03-29 CN disclosed
CN-116554029-A Synthesis method of aromatic formyl ethyl acetate 河北民族师范学院 2023-08-08 CN disclosed
US-20220396567-A1 SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2022-12-15 US disclosed
US-20220396567-A1 SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2022-12-15 US disclosed
EP-4038065-A1 SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2022-08-10 EP disclosed
CN-114450277-A Substituted pyrimidines for the treatment and prevention of hepatitis B virus infection 豪夫迈·罗氏有限公司 2022-05-06 CN disclosed
WO-1998057937-A2 INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-23 WO disclosed
WO-1998038171-A1 PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS SIGNAL PHARMACEUTICALS, INC. (US) 1998-09-03 WO disclosed
WO-1998028269-A1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-07-02 WO disclosed
WO-1997009325-A1 PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS SIGNAL PHARMACEUTICALS, INC. (US) 1997-03-13 WO disclosed
US-4711898-A 4-quinolone derivatives having anti-inflammatory, anti-allergic, antitussive, expectorant and antithrombotic activity NIPPON SHINYAKU CO., LTD. (JP) 1987-12-08 US disclosed
EP-0104959-B1 4-QUINOLONE DERIVATIVES NIPPON SHINYAKU COMPANY, LIMITED (JP) 1987-01-21 EP disclosed
EP-0104959-A1 4-Quinolone derivatives NIPPON SHINYAKU COMPANY, LIMITED (JP) 1984-04-04 EP disclosed
US-4035190-A 2-ISOXAZOLIN-3-HETEROCYCLIC-SUBSTITUTED MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181058-A1 Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives HPD, HAAO, GRHPR ERCC5 3209/4885FEN1 1511/4885NPC1 1532/4885
US-20220396567-A1 SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION TYMP, HPRT1, DPYD ERCC5 366/4885FEN1 316/4885NPC1 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.